| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 148.84 | 3.6% |
| Total Income | 149.71 | 10.9% |
| Expenditure | 135.19 | 13.5% |
| PBT | 14.53 | 23.9% |
| Net Profit | 11.83 | 5.9% |
| OPM | 16.47% | 8.86pp |
| NPM | 7.90% | 1.25pp |
| EPS | 3.85 | 4.9% |
Bajaj Healthcare Delivers Strong Q1 FY26 Results with 66% PAT Growth, 12.5% Revenue Uptick
28 Jul 2025 · 28 Jul 2025, 10:24 pm
Summary
Bajaj Healthcare Limited, one of the leading manufacturers of APIs, Intermediates and Formulations, announced its financial results for the quarter ended 30 June 2025. The company reported a 12.5% year-on-year increase in revenue from operations and a 66% growth in PAT.
Key Highlights
- 1
Revenue from operations rose 12.5% year-on-year to 1,488.4 Mn
- 2
PAT grew by 66% to 118.3 Mn
- 3
EBITDA remained steady at 253.9 million
- 4
API export business delivered standout growth of 68.4% YoY
- 5
Formulations saw 41.1% year-on-year growth
- 6
Received three new CEP approvals and one ASMF approval from European regulatory authority
- 7
Validation batch supplies have commenced for a few molecules under CDMO agreements
- 8
Five DMFs were filed with the UK MHRA to enable future commercial supply and regulatory compliance
- 9
Export contribution rose to 35% of total revenue
- 10
Backward integration continues to be a cornerstone of our strategy
Management Comments
Mr. Anil Jain — Managing Director
Q1 FY26 marks a strong and promising start to the new fiscal year for Bajaj Healthcare, despite a challenging pricing environment in certain segments. Revenue from operations rose 12.5% year-on-year to 1,488.4 Mn, while PAT grew by 66% to 118.3 Mn, reflecting improved profitability and sharper execution across business segments.
Informational and educational content only. Not investment advice.